Free Trial

ICON Public (ICLR) Stock Price, News & Analysis

$302.52
-5.48 (-1.78%)
(As of 09/6/2024 ET)
Today's Range
$300.42
$309.44
50-Day Range
$302.52
$346.20
52-Week Range
$221.20
$347.72
Volume
277,775 shs
Average Volume
546,048 shs
Market Capitalization
$24.96 billion
P/E Ratio
36.80
Dividend Yield
N/A
Price Target
$352.56

ICON Public MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
16.5% Upside
$352.56 Price Target
Short Interest
Healthy
1.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of ICON Public in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.34%
From $14.54 to $16.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.63 out of 5 stars

Medical Sector

226th out of 910 stocks

Commercial Physical Research Industry

5th out of 11 stocks

ICLR stock logo

About ICON Public Stock (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

ICLR Stock Price History

ICLR Stock News Headlines

War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Celebrating movie icons: Robert Duvall
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
iOS 18: Make Your iPhone Home Screen Icons Dark
ICON PLC (ICLR) Earnings Dates & Reports
Barclays Reaffirms Their Buy Rating on Icon (ICLR)
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/24/2024
Today
9/07/2024
Next Earnings (Estimated)
10/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
NASDAQ:ICLR
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$352.56
High Stock Price Target
$383.00
Low Stock Price Target
$315.00
Potential Upside/Downside
+16.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$612.34 million
Pretax Margin
9.05%

Debt

Sales & Book Value

Annual Sales
$8.33 billion
Cash Flow
$18.28 per share
Book Value
$116.19 per share

Miscellaneous

Free Float
46,197,000
Market Cap
$24.96 billion
Optionable
Optionable
Beta
1.22

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. John Climax Ph.D. (Age 71)
    Founder & Independent Non-Executive Director
    Comp: $90k
  • Mr. Brendan  BrennanMr. Brendan Brennan (Age 45)
    Chief Financial Officer
    Comp: $1.07M
  • Dr. Steven A. Cutler MBA (Age 64)
    Ph.D., CEO & Director
    Comp: $2.54M
  • Jonathan Andrew Curtain (Age 48)
    Senior Vice President of Corporate & Commercial Finance
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 49)
    Chief Administrative Officer, General Counsel & Company Secretary
  • Ms. Niamh Murphy
    Director of Corporate Communications
  • Mr. David Green
    Vice President of Marketing
  • Mr. Joe Cronin
    Chief Human Resources Officer
  • Mr. Simon Holmes (Age 57)
    President of Corporate Investments & Partnerships

Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public's short interest has expanded by 12.2%, indicating potential positive sentiment among investors.
  • Analysts have been upgrading their price targets for ICON Public, with a consensus price target of $352.56, suggesting growth potential.
  • William Blair raised their FY2024 EPS estimates for ICON Public, projecting earnings of $14.63 per share, which could attract investors seeking strong earnings growth.
  • ICON Public's recent quarterly earnings beat analysts' estimates, showing strong financial performance and potential for future growth.
  • ICON Public's stock price has been trading up, reaching $329.33, which may indicate positive momentum and investor confidence.

Cons

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • Short interest in ICON Public has increased, which could indicate potential volatility or uncertainty in the market.
  • Some analysts have lowered their price targets for ICON Public, which may suggest concerns about future performance.
  • While the FY2024 EPS estimates were raised, there is always a risk of not meeting these heightened expectations, leading to potential disappointment among investors.
  • The stock's 50-day moving average is $322.17, which could signal a potential resistance level for the stock price.
  • ICON Public's fifty-two week high of $347.72 may pose a challenge for further significant price appreciation in the near term.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 26, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICLR Stock Analysis - Frequently Asked Questions

How have ICLR shares performed this year?

ICON Public's stock was trading at $283.07 on January 1st, 2024. Since then, ICLR shares have increased by 6.9% and is now trading at $302.52.
View the best growth stocks for 2024 here
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) announced its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $3.75 EPS for the quarter, beating the consensus estimate of $3.68 by $0.07. The firm's quarterly revenue was up 4.1% on a year-over-year basis.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Does ICON Public have any subsidiaries?

The following companies are subsidiaries of ICON Public: PRA Health Sciences, MedPass International, MeDiNova Research, MolecularMD, Mapi Group, Clinical Research Management, PMG Research, and more.

Who are ICON Public's major shareholders?

Top institutional shareholders of ICON Public include Liontrust Investment Partners LLP (0.15%), Kornitzer Capital Management Inc. KS (0.12%), Susquehanna International Group LLP and Millennium Management LLC.

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH) and Alibaba Group (BABA).

This page (NASDAQ:ICLR) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners